Oscar Health's scale is finally producing real operating leverage as its medical loss ratio improves, undercutting the view that it is uninvestable. Q1 revenue rose 53% to $4.65 billion, operating earnings 137% to $704 million, net income 147% to $679 million and basic EPS 107% to $2.28. x.com 

Oscar Health is too cheap after guiding full-year results about 40% above street estimates, and should be trading above $20. Per @Pharmdca, Oscar expects $18.7B-$19B of 2026 revenue, up 61% on record membership and AI efficiencies, is on track to return to profitability, and CEO Mark Bertolini bought about $11.92M of shares. The stock should have risen 5-6% when it reiterated that guidance. x.com  x.com 

Oscar Health's raised 2026 guidance changes nothing fundamentally, so its 18%+ premarket jump is unlikely to hold. Operating earnings guidance rose to $500-700M from $250-450M, but Oscar had already booked $704M in Q1 alone, more than the new top end, with Q3 and Q4 seasonally bringing losses. 2027 could be challenging as management targets a 5% margin, and the stock looks fairly valued around $34. x.com  x.com 

Oscar Health's run has just started. The market liked the CEO buying stock, the reaffirmed 2026 guidance and last quarter's first-ever operating profit. x.com  x.com 

Oscar Health's downside case looks too aggressively priced after it held support through the March-April capitulation and rebounded sharply. A strong Q1 brought higher revenue, a better medical loss ratio, significant adjusted EBITDA and reaffirmed 2026 guidance, and its tech-enabled ACA platform could deliver meaningful operating leverage. A sustained close above about $20, a multi-year ceiling, would open a path toward its IPO highs. ACA subsidy and eligibility changes remain a real risk. … Show more

Oscar Health looks too extended after its big move and should pull back around earnings in the next few days; it is not a tech stock with a niche product capable of parabolic moves. x.com 

Oscar Health's record Q1 and CEO insider buying set it up to break out of a 24-month accumulation base. The tech-driven insurer, spanning ACA, Medicare and small-group markets, grew revenue 53% and earned $2.07 a share versus $1.11 expected, and its CEO bought 1 million shares in April. A clean close above $24, where it has been rejected repeatedly, is needed before it heads higher. x.com 

Oscar Health is valued at less than 1x trailing sales, a wild valuation for a business still growing at its pace. It generated $11 billion of revenue last year and trades at a market cap of roughly $9 billion. x.com 

Oscar Health cannot be a great business because insurance, like banking, is uninvestable when its economics are nearly impossible to predict. One bad cycle or change in costs can wipe out margins that are already nonexistent. A post the author replies to argues Oscar avoided the 30-40% member drop the market expected after enhanced premium tax credits expired. x.com 

Oscar Health's guidance raise shows improving operating leverage, the key test of whether its ACA growth can become durable profit. It lifted 2026 earnings from operations guidance to $600M-$800M from $500M-$700M while leaving revenue guidance unchanged at $18.7B-$19.0B, and improved medical loss ratio guidance by 50 bps to 81.0%-82.0%. The implied operating margin rises from about 3.2% to 3.7% without more revenue. ACA risk adjustment and medical-cost trends still need watching. x.com  x.com